Alnylam Pharma (ALNY) Tops Q3 EPS by $3.06

Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of $1.74, $3.06 better than the analyst estimate of ($1.32). Revenue for the quarter came in at $750.5 million versus the consensus estimate of $397.99 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• 374Water Inc (SCWO) Misses Q2 EPS by 15c
• Prenetics Global (PRE) Tops Q2 EPS by 18c